The Zika virus, a member of the Flaviviridae family that was originally spread by daytime-active Aedes mosquitoes, has already provided an ideal demonstration that Avacta’s Affimer platform can very quickly develop highly specific reagents in response to an outbreak of an infectious disease.
The Group’s global technology partnership with Cytiva announced today now provides it with immediate access to a COVID-19 diagnostic, which is essential if a practical and commercial solution is to be promptly offered to governments and healthcare providers around the world.
Affimer-based tools can be designed rapidly and specifically for identified epitopes, while Cytiva’s support in the form of technology transfer and usability should ensure a test is ready at the earliest point for use in the field. Potentially this provides Avacta with not only a reputation building, high-profile new product of global significance, but also near and longer-term commercial opportunities for its platform.
Avacta, the developer of Affimer® technology and pre|CISION chemotherapies, has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
The World Health Organisation (‘WHO’) recently highlighted the need for the development of rapid tests to quickly diagnose COVID-19 at point-of-care to assist in limiting and tracking infections. Existing tests are not suitable for screening large numbers of people for the infection as they are laboratory-based and it can take up to several days to get the results
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
RISK WARNING: The value of shares and the income from them may go down as well as up and you may not get back the money you invested. It should not be assumed that the value of investments will always rise. Past performance is not a reliable indicator of future results and any investment in shares carries the risk that all or some of the capital invested might be lost. Investors should carefully consider their own personal financial circumstances before dealing in the stock market and should seek independent professional advice prior to investing. Investors should ensure that they have the financial capacity to bear the risk and only invest money you can afford to lose.
RISK WARNING – INVESTING IN SMALLER COMPANIES: Companies listed on the AIM market can be highly volatile and are considered high risk speculative investments. You should only consider investing in AIM shares if you have an appropriate degree of equity trading knowledge and experience. It may be difficult to sell the shares on a short-term basis without receiving a significantly lower price than you paid. This is the nature of illiquid investments and their large spread.
Turner Pope Investments (TPI) Limited copyright
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned